Intravenous inoculation of a group A hemolytic streptococcus caused lethal infections in all of eight untreated monkeys. Intramuscular injections of clindamycin-2-phosphate in a daily dose of 25 mg/kg given in equal morning and afternoon doses for 10 days resulted in survival of all of eight monkeys. Similar results were observed with the same dose schedule of clindamycin hydrochloride given intragastrically; no fatalities occurred among eight monkeys. In monkeys receiving erythromycin stearate intragastrically or methicillin intramuscularly, three of eight and four of eight monkeys, respectively, died. Duration of both illness and positive blood cultures was greater in the erythromycin-and methicillin-treated survivors than in the clindamycin-treated monkeys. The differences in results between clindamycin and erythromycin could not be correlated with serum antibacterial activity levels, which were similar, or with minimal inhibitory concentrations, which were 0.02 ,ug/ml with both antibiotics. With methicillin, however, the minimal inhibitory concentration was 0.16 ,ug/ml and serum antibacterial activity varied from titers of less than 1:2 to 1: 8. As in previous studies of staphylococcal infections in monkeys with the same antibiotics, in vitro susceptibility data and serum antibacterial activity did not completely correlate with in vivo results.
Previous studies demonstrated similar efficacy with reference to mortality of monkeys with severe staphylococcal sepsis after therapy with intragastric clindamycin hydrochloride or erythromycin stearate or intramuscular clindamycin-2-phosphate or methicillin (1) . The purpose of this study was to compare the oral and injectable forms of clindamycin in streptococcal sepsis. As in the staphylococcal study, erythromycin stearate and methicillin were also included for comparative purposes.
MATERIALS AND METHODS
Forty fully conditioned monkeys (Macaca mulatta) weighing 2.8 to 3.9 kg were used. Intravenous challenge with the Stollerman T14 strain of Streptococcus hemolyticus group A was conducted after a 2-week period of base-line physical examinations and bacteriological and serological studies, as previously described (6, 9, 10) . Therapy was initiated 8 hr after challenge when monkeys were lethargic, weak, and anorectic but not acutely ill. The daily dose of 25 mg/kg was divided equally and given by gastric tube (clindamycin hydrochloride and erythromycin stearate) or intramuscularly (clindamycin-2-phosphate and methicillin) at 8:00 AM and 5:00 PM for 10 days; infected controls received distilled water intragastrically or saline intramuscularly. Food was withheld for at least 1 hr after the morning dose. Clindamycin hydrochloride capsules and injectable solution of clindamycin-2-phosphate were kindly provided by R. M. DeHaan; erythromycin stearate tablets and methicillin were purchased from a local pharmacy. Oral suspensions were prepared from tablets and contents of capsules as described previously (1) .
Monkeys were examined at least twice daily for 3 weeks after challenge, and then daily thereafter for at least 3 months. Duration of "acute illness" included days in which the monkey was markedly anorectic, lethargic, and weak, and did not respond to stimuli; it would lie in the cage huddled up. "Total illness" included both acute and convalescent periods until the animal again became freely active, vigorous, and alert. Laboratory studies included blood cultures, C-reactive protein (CRP) tests, antistreptolysin 0 (ASO) titers, blood urea nitrogen (BUN) and serum glutamic-pyruvic transaminase (SGPT) levels, and serum antibacterial activity (ABA) against the challenge streptococcus. Autopsies were performed on all fatally infected animals.
Serum ABA was measured as previously described (2, 3) . Minimal inhibitory concentrations (MIC) of clindamycin base, erythromycin base, and methicillin streptococci, respectively. All monkeys in both studies were weak, lethargic, and anorectic when therapy was started 8 hr after challenge. The eight untreated control monkeys became progressively worse, and all were dead by the afternoon of day 2. Hemorrhage and congestion of the lungs, pericardial effusion, and splenomegaly were the main findings at autopsy; group A streptococci were isolated from heart blood and all major organs of all eight monkeys.
All 16 monkeys treated with either of the two clindamycin preparations survived, whereas 3 of 8 and 4 of 8 monkeys given erythromycin stearate and methicillin, respectively, did not respond to therapy and died ( Table 1 ). The eight survivors treated with clindamycin hydrochloride were acutely ill for 2 to 3 days (mean, 2.5 days), recovered rapidly, and appeared normal after 3 to 4 days (mean, 3.9 days). Similarly, acute illness was observed for 2 to 5 days (mean, 2.8 days) in eight monkeys given clindamycin-2-phosphate, and all were apparently fully recovered after 3 to 6 days (mean, 4.0 days).
Two monkeys treated with erythromycin stearate died abotut 36 hr after challenge after having received two doses of antibiotic. Gross pathology was similar to that observed in untreated control monkeys, and all major organs and heart blood yielded group A streptococci. A third monkey in experiment 2 (no. 31, Table 3) showed no response to therapy during the first 5 days. On day 6, cellulitis involving the upper half of the face and particularly the orbits was observed. In addition, evidence of epistaxis was noted. Group A streptococci were isolated by nasal swab and by needle aspiration of the area of cellulitis. The monkey became worse on day 7 and was moribund at 8:00 AM on day 8 when the morning dose of erythromycin was given; it died about 5 hr later. At autopsy, the lungs were markedly hemorrhagic and the trachea was filled with frothy blood-tinged fluid. None of the major organs or heart blood yielded streptococci when cultured, and blood cultures obtained on days 3, 4, 6, and 8 were negative. As can be seen in Table 3 , the high ABA levels may have prevented recovery of the organism. The BUN on day 2 was 462 CARLISLE Al on day 6, as compared to 13 mg/100 ml prior to challenge. Serum samples obtained from this monkey on days 6 and 8 before the morning dose, i.e., about 16 hr after the afternoon dose on the previous day, showed an ABA titer of 1:16 on both days; no ABA was detected at the same time interval on either day in the other two erythromycin-treated survivors. Thus, three treatment failures were observed in the group of eight monkeys given erythromycin stearate. The five surviving monkeys were extremely weak, lethargic, and anorectic for 2 to 6 days (mean, 4.0 days) and did not recover fully until after 4 to 8 days (mean, 5.6 days). Four of eight monkeys treated with methicillin did not respond to therapy, and were dead by the afternoon of day 2 after having received from two to four doses (Table 1) . Group A streptococci N4D SASLAW ANTIMICROB. AG. CHEMOTHER.
were isolated from all major organs and heart blood of all four monkeys. Two (no. 15 and 36, Tables 2 and 3 ) of four surviving monkeys began to improve after only 2 days of therapy, and both appeared normal on day 4 and thereafter. The other two monkeys (no. 16 and 35) remained acutely ill for 5 and 10 days, respectively, and did not recover fully until days 7 and 15, respectively. Positive blood cultures were obtained during the therapy period from only two of eight monkeys treated with clindamycin hydrochloride and from only one of eight monkeys given clindamycin-2-phosphate, as shown in Table 2 . Blood cultures were negative in all 16 monkeys after the 10-day treatment period. In contrast, all four surviving methicillin-treated monkeys and three of five monkeys surviving after erythromycin stearate exhibited positive blood cultures while on Serum ABA of samples obtained 2 hr after the 8:00 AM dose on therapy days 2 and 9 are shown in Table 3 . MIC values of clindamycin base, erythromycin base, and methicillin for the challenge streptococcus were 0.02, 0.02 and 0.16 g/rml, respectively. Monkeys given clindamycin hydrochloride intragastrically showed ABA titers of 1: 128 to 1:1,024 on day 2 and 1: 32 to 1:256 on day 9. Comparable high ABA titers were observed at the same time intervals after clindamycin-2-phosphate and erythromycin stearate. In contrast, monkeys receiving methicillin showed less serum ABA; titers of <1:2 to 1:8 were observed, as shown in Table 3 .
As in previous studies (6, 9, 10) BUN levels were frequently increased as a result of infection on day 2 during the acute illness and returned to normal by day 9 after recovery. Thus, some of the differences in ABA titers in individual monkeys on days 2 and 9 could be attributed, in part, to retention of antibiotics, as shown in Table 3 .
Significant increases in ASO titer were noted in all of the five surviving monkeys treated with erythromycin stearate and in three of the four survivors given methicillin. In contrast, only five of eight and four of eight monkeys treated with clindamycin hydrochloride and clindamycin-2-phosphate, respectively, showed significant ASO titer changes. These differences may be related, in part, to the apparently earlier elimination of the streptococcus in the clindamycin-treated monkeys. DISCUSSION In a study at this institution to evaluate the efficacy of clindamycin in patients, this antibiotic was found to be especially effective in soft tissue infections (R. J. Fass and S. Saslaw, in press).
These infections were most often due to hemolytic streptococci, to penicillin-susceptible or resistant staphylococci, or to both streptococci and staphylococci. A previous study in monkeys compared the effect of clindamycin, erythromycin, and methicillin in infections caused by a penicillin-resistant staphylococcus (1). Since staphylococcal and streptococcal infections may at times be confused clinically or coexist, the present studies on streptococcal infection were instituted to compare the same antibiotics employed in the staphylococcal study.
After administration of clindamycin hydro- (1, 5, 7, 8, 11, 12) and streptococcal (6, 9, 10) 
